• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Association of Opioid Use Disorder and COVID-19, a Longitudinal Study.阿片类物质使用障碍与2019冠状病毒病的关联：一项纵向研究
Int J Prev Med. 2022 Dec 26;13:157. doi: 10.4103/ijpvm.ijpvm_68_22. eCollection 2022.
2
Outcomes of patients with COVID-19 in the setting of chronic opioid use disorder.慢性阿片类药物使用障碍患者 COVID-19 的结局。
J Opioid Manag. 2022 Nov-Dec;18(6):523-528. doi: 10.5055/jom.2022.0747.
3
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.医疗保险受益人的远程医疗服务的接受情况、阿片类药物使用障碍药物的获得和保留情况，以及在 COVID-19 大流行之前和期间的药物治疗过量情况。
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.
4
"How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.“我下周的药方该怎么办？”Reddit阿片类药物论坛用户对新冠疫情最初几个月治疗获取方面变化的反应。
Int J Drug Policy. 2021 Jun;92:103140. doi: 10.1016/j.drugpo.2021.103140. Epub 2021 Feb 6.
5
Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care.在接受综合门诊临床护理的阿片类药物使用障碍患者中，新冠病毒疾病发病率与普通人群相似。
Drug Alcohol Depend Rep. 2022 Mar;2:100027. doi: 10.1016/j.dadr.2022.100027. Epub 2022 Jan 15.
6
Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study.阿片受体 μ 型 1 功能编码变异与阿片类药物使用障碍的关联：一项全基因组关联研究。
JAMA Psychiatry. 2020 Oct 1;77(10):1072-1080. doi: 10.1001/jamapsychiatry.2020.1206.
7
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.在 COVID-19 应对期间，在注射毒品者的注射器服务项目中治疗丙型肝炎病毒：远程医疗、阿片类药物使用障碍治疗药物和对患者低要求的潜在作用。
Int J Drug Policy. 2022 Mar;101:103570. doi: 10.1016/j.drugpo.2021.103570. Epub 2021 Dec 20.
8
Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis.阿片类物质使用障碍与 COVID-19 感染风险及相关住院、重症监护病房入院和死亡率的关系：系统评价和荟萃分析。
Addict Sci Clin Pract. 2022 Nov 30;17(1):68. doi: 10.1186/s13722-022-00349-8.
9
Association of chronic opioid therapy and opioid use disorder with COVID-19-related hospitalization and mortality: Evidence from three health systems in the United States.慢性阿片类药物治疗及阿片类药物使用障碍与新冠病毒相关住院治疗和死亡率的关联：来自美国三个医疗系统的证据
Prev Med Rep. 2024 Jul 25;46:102832. doi: 10.1016/j.pmedr.2024.102832. eCollection 2024 Oct.
10
Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.2011 年至 2014 年期间，马萨诸塞州接受阿片类药物处方的阿片类药物初治人群中阿片类药物使用障碍和过量的趋势。
Addiction. 2020 Mar;115(3):493-504. doi: 10.1111/add.14867. Epub 2019 Dec 21.

引用本文的文献

1
Opioid Treatment Programs and Risks for COVID-19 Infections, Emergency Visits, and Hospitalizations.阿片类药物治疗项目与感染新型冠状病毒、急诊就诊及住院的风险
J Gen Intern Med. 2025 Feb 25. doi: 10.1007/s11606-025-09444-3.

本文引用的文献

1
COVID-19 transmission risk factors.COVID-19 传播风险因素。
Pathog Glob Health. 2022 May;116(3):146-177. doi: 10.1080/20477724.2021.1993676. Epub 2021 Dec 28.
2
Correction: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States.更正：物质使用障碍患者的COVID-19风险与结局：来自美国电子健康记录的分析
Mol Psychiatry. 2021 Jan;26(1):40. doi: 10.1038/s41380-020-00895-0.
3
COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper.2019冠状病毒病与物质使用障碍：全面医疗应对建议。国际成瘾医学学会实践与政策兴趣小组立场文件
Basic Clin Neurosci. 2020 Mar-Apr;11(2):133-150. doi: 10.32598/bcn.11.covid19.1. Epub 2020 Apr 12.
4
Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability?阿片类药物与新冠疫情：长期使用或滥用阿片类药物会增加临床易感性吗？
Br J Anaesth. 2020 Oct;125(4):e382-e383. doi: 10.1016/j.bja.2020.07.004. Epub 2020 Jul 19.
5
A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19.烟草花叶病毒可能在吸烟者对 COVID-19 的抵抗力中起作用。
Med Hypotheses. 2020 Oct;143:110153. doi: 10.1016/j.mehy.2020.110153. Epub 2020 Jul 31.
6
Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review.绿茶和红茶多酚在预防和治疗 COVID-19 中的抗病毒活性：综述。
Phytomedicine. 2021 May;85:153286. doi: 10.1016/j.phymed.2020.153286. Epub 2020 Jul 17.
7
COVID-19 pandemic and addiction: Current problems in Iran.新冠疫情与成瘾：伊朗当前的问题
Asian J Psychiatr. 2020 Dec;54:102313. doi: 10.1016/j.ajp.2020.102313. Epub 2020 Jul 23.
8
COVID-19 and persons with substance use disorders: Inequities and mitigation strategies.新型冠状病毒肺炎与物质使用障碍患者：不公平现象与缓解策略。
Subst Abus. 2020;41(3):286-291. doi: 10.1080/08897077.2020.1784363.
9
Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes.阿片类药物使用障碍与 COVID-19：结局恶化的生物学推测。
Subst Use Misuse. 2020;55(11):1900-1901. doi: 10.1080/10826084.2020.1791184. Epub 2020 Jul 12.
10
Opioid Use Disorder Treatment and Potential Interactions With Novel COVID-19 Medications: A Clinical Perspective.阿片类物质使用障碍的治疗及与新型 COVID-19 药物的潜在相互作用：临床视角
Prim Care Companion CNS Disord. 2020 Jul 2;22(4):20com02703. doi: 10.4088/PCC.20com02703.

阿片类物质使用障碍与2019冠状病毒病的关联：一项纵向研究

The Association of Opioid Use Disorder and COVID-19, a Longitudinal Study.

作者信息

Jamali Zhaleh, Emamian Mohammad Hassan, Hashemi Hassan, Fotouhi Akbar

机构信息

Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.

Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.

出版信息

Int J Prev Med. 2022 Dec 26;13:157. doi: 10.4103/ijpvm.ijpvm_68_22. eCollection 2022.

DOI:10.4103/ijpvm.ijpvm_68_22
PMID:36910999
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9999101/
Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) quickly spread to the world, causing a pandemic. While some studies have found no link between opioid use disorder (OUD) and COVID-19, the role of opioid on COVID-19 is challenging. The present study aimed to determine the relationship between OUD and COVID-19.

METHODS

This was a prospective cohort study. We used data from the third phase of the Shahroud Eye Cohort Study on 4394 participants which started in September 2019 and ended before the COVID-19 epidemic in Shahroud in February 2020. The participants were followed for about 13 months till March 26, 2021. COVID-19 was detected by RT-PCR on swap samples from the oropharynx and nasopharynx. The incidence of COVID-19 compared in OUD and non-OUD participants, and relative risk was calculated in log-binomial regression models.

RESULTS

Among the 4394 participants with a mean age of 61.1 years, 120 people had OUD. The incidence of COVID-19 in participants with OUD and non-OUD was 4.17% and 6.22%, respectively (P-value: 0356). The relative risk of OUD for COVID-19 was 0.60 (95% confidence intervals: 0.25-1.44; value: 0.251).

CONCLUSIONS

OUD was not associated with COVID-19. The claim that people with OUD are less likely to develop COVID-19 is not supported by these data.

摘要

背景

2019年冠状病毒病（COVID-19）迅速蔓延至全球，引发了一场大流行。虽然一些研究未发现阿片类物质使用障碍（OUD）与COVID-19之间存在关联，但阿片类物质对COVID-19的作用仍具有挑战性。本研究旨在确定OUD与COVID-19之间的关系。

方法

这是一项前瞻性队列研究。我们使用了2019年9月开始、2020年2月设拉子COVID-19疫情爆发前结束的设拉子眼队列研究第三阶段中4394名参与者的数据。对参与者进行了约13个月的随访，直至2021年3月26日。通过对来自口咽和鼻咽的拭子样本进行逆转录聚合酶链反应（RT-PCR）检测COVID-19。比较了OUD参与者和非OUD参与者中COVID-19的发病率，并在对数二项回归模型中计算了相对风险。

结果

在平均年龄为61.1岁的4394名参与者中，有120人患有OUD。患有OUD和未患有OUD的参与者中COVID-19的发病率分别为4.17%和6.22%（P值：0.356）。OUD患COVID-19的相对风险为0.60（95%置信区间：0.25 - 1.44；P值：0.251）。

结论

OUD与COVID-19无关。这些数据不支持OUD患者感染COVID-19的可能性较小这一说法。